Details of the Drug
General Information of Drug (ID: DMJKBAY)
Drug Name |
NGX-267
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
503431-81-0; AF267B; (2S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4,5]DECAN-3-ONE; UNII-8D3PZX7G73; AF 267B; 8D3PZX7G73; (S)-2-Ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one; NGX-267; NGX267; NGX 267; SCHEMBL3651146; CTK1G8674; DTXSID40198399; AF-267B; PHOZOHFUXHPOCK-QMMMGPOBSA-N; ZINC13816318; AKOS025295388; NCGC00162382-01; RT-005412; FT-0668336; (S)-2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one; 1-Thia-4,8-diazaspiro(4.5)decan-3-one, 2-ethyl-8-methyl-, (2S)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 214.33 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Schizophrenia | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 6A20 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References